A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)

Trial Profile

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Ombitasvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Paritaprevir (Primary) ; Ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PEARL-I
  • Sponsors AbbVie
  • Most Recent Events

    • 24 Nov 2015 According to an AbbVie media release, ombitasvir/paritaprevir/ritonavir [Technivie] tablets in combination with ribavirin have received an approval from Health Canada for the treatment of adults with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis who are either treatment naive or previously treated with peginterferon and ribavirin.
    • 17 Aug 2015 Results published in the Antimicrobial Agents and Chemotherapy.
    • 24 Jul 2015 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top